الملخص
Objectives: This study aimed to evaluate the effectiveness of an established respiratory syncytial virus (RSV) prophylaxis programme by assessing RSV-related hospitalisations (RSVH) and identify associated risk factors among preterm infants born at <32 weeks’ gestation. Methods: This retrospective cohort study was conducted at Sultan Qaboos University Hospital, Muscat, Oman. Eligible participants were preterm infants <32 weeks’ gestation, born between January 2015 and December 2020, who received RSV prophylaxis. Data were extracted from electronic medical records and analysed. Results: A total of 282 infants were included. The mean gestational age was 28.56 ± 2.03 weeks and the mean birth weight was 1.23 ± 0.35 kg. A total of 5 infants (1.8%) experienced RSV-related hospitalisation while receiving palivizumab prophylaxis. Infants with RSVH were significantly more likely to be born at <28 weeks’ gestation than those who had not had a RSVH (60% versus 26.7%; P = 0.033). The rate of bronchopulmonary dysplasia was significantly higher in RSVH infants compared to those without RSVH (60% versus 14.1%; P = 0.026). Conclusion: The RSV prophylaxis programme demonstrated effectiveness, with a low RSVH rate among high-risk preterm infants. Extreme prematurity and bronchopulmonary dysplasia are the most significant risk factors for RSVH. Despite being a single-centre retrospective study, this is the first evaluation of RSV immunoprophylaxis in Oman and supports the case for a nationwide programme targeting high-risk infants.
بيانات النشر
- المعرّف الرقمي
- 10.18295/2075-0528.2955
- المجلة
- مجلة جامعة السلطان قابوس الطبية, 26(1), 45-50
- الناشر
- جامعة السلطان قابوس
- وصول مفتوح
- وصول مفتوح ذهبي
- الترخيص
- CC BY-ND 4.0
اقتبس هذه المقالة
APA 7
Al Mandhari, H., Al Kendi, S., Al-Balushi, N., Bintaqi, A., Al Saadi, A., & Abdellatif, M. (2026). The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study. Sultan Qaboos University Medical Journal, 26(1), 45-50. https://doi.org/10.18295/2075-0528.2955
MLA 9
Al Mandhari, Hilal, et al. "The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study." Sultan Qaboos University Medical Journal, vol. 26, no. 1, 2026, pp. 45-50. https://doi.org/10.18295/2075-0528.2955.
شيكاغو (المؤلف–التاريخ)
Al Mandhari, Hilal, Saif Al Kendi, Noura Al-Balushi, Aqeela Bintaqi, Abdulrahman Al Saadi, and Mohamed Abdellatif. 2026. "The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study." Sultan Qaboos University Medical Journal 26 (1): 45-50. https://doi.org/10.18295/2075-0528.2955.
هارفارد
Al Mandhari, H., Al Kendi, S., Al-Balushi, N., Bintaqi, A., Al Saadi, A. and Abdellatif, M. (2026) 'The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study', Sultan Qaboos University Medical Journal, 26(1), pp. 45-50. doi:10.18295/2075-0528.2955.
فانكوفر
Al Mandhari H, Al Kendi S, Al-Balushi N, Bintaqi A, Al Saadi A, Abdellatif M. The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study. Sultan Qaboos University Medical Journal. 2026;26(1):45-50. doi:10.18295/2075-0528.2955
IEEE
H. Al Mandhari, S. Al Kendi, N. Al-Balushi, A. Bintaqi, A. Al Saadi, and M. Abdellatif, "The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: A single institute retrospective study," Sultan Qaboos University Medical Journal, vol. 26, no. 1, pp. 45-50, 2026, doi: 10.18295/2075-0528.2955.